|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||27.83 - 29.48|
|52 Week Range||20.60 - 40.47|
|Beta (5Y Monthly)||0.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||72.00|
Relmada Therapeutics, Inc. (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Shares of Relmada Therapeutics (NASDAQ: RLMD), a clinical-stage biopharmaceutical company, popped in response to a positive clinical trial readout with the company's lead candidate. Investors excited about REL-1017's positive human abuse potential trial results pushed the stock 37% higher at its peak this morning. Relmada Therapeutics has settled down since its early morning pop.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...